Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Brief Summary: This is a Phase 1, open-label, multicenter study evaluating the safety and PK profile of ABT-199 under a once daily dosing schedule. Two arms will be implemented for dose escalation: Arm A, CLL/SLL subjects and Arm B, NHL subjects. Arm A is designed to enroll approximately 116 subjects with relapsed or refractory CLL or SLL and Arm B is designed to enroll approximately 95 subjects with relapsed or refractory NHL. Fifty-six subjects were enrolled in Arm A and approximately 55 subjects will be enrolled in Arm B during the dose escalation portion of the study, with the objective of defining dose limiting toxicities (DLTs) and the MTD. Once the MTD is declared for the arm, approximately 60 additional CLL/SLL subjects in Arm A and approximately 20 additional DLBCL subjects and 20 additional follicular lymphoma subjects in Arm B will be enrolled in an expanded safety portion of the study at the recommended phase 2 dose (RPTD) and schedule.


Options:
A: Arm Label: Arm A (CLL/SLL subjects); Type: EXPERIMENTAL; Interventions: Drug: ABT-199 | Arm Label: Arm B (NHL subjects); Type: EXPERIMENTAL; Interventions: Drug: ABT-199 | Intervention Type: DRUG; Name: ABT-199; Assigned to Arm(s): Arm A (CLL/SLL subjects), Arm B (NHL subjects)
B: Arm Label: Phase I, NHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: Phase I, CLL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 400/400 mg - Phase II, iNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1600/800 mg - Phase II, iNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 400/400 mg - Phase II, aNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1600/800 mg - Phase II, aNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1000/1000 mg - Phase II, CLL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: Retreated Participants; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): 1000/1000 mg - Phase II, CLL, 1600/800 mg - Phase II, aNHL, 1600/800 mg - Phase II, iNHL, 400/400 mg - Phase II, aNHL, 400/400 mg - Phase II, iNHL, Phase I, CLL, Phase I, NHL, Retreated Participants
C: Arm Label: Experimental: 1; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide | Arm Label: Placebo Comparator: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Experimental: 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator: 2
D: Arm Label: Bendamustine, rituximab, lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Rituximab, Drug: Lenalidomide | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine, rituximab, lenalidomide | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Bendamustine, rituximab, lenalidomide | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Bendamustine, rituximab, lenalidomide

Answer: A